Here you can find all archived newsletters.
- 20 August 2021 – Your German Market Access News!
- 3 September 2021 – Your German Market Access News!
- 17 September 2021 – Your German Market Access News! – 17 Sep 2021
- 28 September 2021 – Your German Market Access News! – 28 Sep 2021
- 12 October 2021 – Your German Market Access News! – 12 Oct 2021
- 19 October 2021 – Your German Market Access News! – 19 Oct 2021
- 26 October 2021 – Your German Market Access News! – 26 Oct 2021
- 2 November 2021 – Case study slide for you to use
- 9 November 2021 – The G-BA restricts the reimbursement of another drug!
- 16 November 2021 – Cell and gene therapies – benefit assessment and quality assurance requirements
- 23 November 2021 – The G-BA embraces digital health applications (DiGA) and telemedicine
- 30 November 2021 – Is the end to the free pricing period coming?
- 7 December 2021 – New German government plans AMNOG reforms
- 14 December 2021 – New German health minister might bring AMNOG changes
- 23 December 2021 – Happy Holidays! Find a little gift inside this newsletter
- 14 January 2022 – The four most important things to know about drug prices in Germany
- 21 January 2022 – Confused about drug prices in Germany?
- 28 January 2022 – Do you know your way around the Lauer Taxe? – A quick-start help guide
- 4 February 2022 – How much does a certain treatment cost in Germany? – What you need to know
- 11 February 2022 – Are you interested in drug reimbursement in Germany? – Get up to speed here
- 18 February 2022 – Happy with your knowledge on the reimbursement of medical devices in Germany?
- 25 February 2022 – Want to know the key differences between SHI and private health insurance in Germany?
- 4 March 2022 – Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
- 11 March 2022 – Which endpoints are important to the G-BA and IQWiG?
- 18 March 2022 – BREAKING NEWS! Upcoming changes to early benefit assessment and pricing
- 25 March 2022 – How does the G-BA pick the appropriate comparator?
- 1 April 2022 – How will German early benefit assessments change in the future?
- 8 April 2022 – Disease management programmes in Germany – IQWiG says it’s time for an update
- 15 April 2022 – Surprisingly, the BMG has withdrawn their draft on legislation changes again
- 22 April 2022 – Which quality requirements apply to ATMPs in Germany?
- 29 April 2022 – Minimum case numbers in Germany
- 6 May 2022 – Quality contracts are trialled to improve the quality of hospital treatments in Germany
- 13 May 2022 – The German Health Minister reveals his plans for the next months
- 20 May 2022 – What’s important to know about real-world evidence data collection in Germany?
- 27 May 2022 – IQWiG finds problems with the use of RWE in manufacturers’ dossiers
- 3 June 2022 – Will the EU regulation for medical devices result in withdrawals or shortages?
- 10 June 2022 – KBV and GKV-SV agreed new clinician fees for DiGAs in Germany
- 17 June 2022 – Virtual consultations for patients with Covid-19 requiring intensive care introduced into routine clinical practice
- 24 June 2022 – G-BA defines 4 strict requirements on cefiderocol use to protect its “reserve antibiotics” status
- 1 July 2022 – IQWiG methods for RWE collection for products of same active ingredient class
- 8 July 2022 – How to bring innovation into German routine clinical practice?
- 15 July 2022 – German Health minister presents new draft of act to stabilise SHI fund finances